Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Times Interest Earned (2019 - 2022)

Historic Times Interest Earned for Keros Therapeutics (KROS) over the last 4 years, with Q1 2022 value amounting to -$24126.0.

  • Keros Therapeutics' Times Interest Earned fell 5299.64% to -$24126.0 in Q1 2022 from the same period last year, while for Dec 2022 it was -$114790.0, marking a year-over-year decrease of 71450.34%. This contributed to the annual value of -$114790.0 for FY2022, which is 71450.34% down from last year.
  • As of Q1 2022, Keros Therapeutics' Times Interest Earned stood at -$24126.0, which was down 5299.64% from -$4866.0 recorded in Q4 2021.
  • Over the past 5 years, Keros Therapeutics' Times Interest Earned peaked at -$775.33 during Q3 2019, and registered a low of -$24126.0 during Q1 2022.
  • For the 4-year period, Keros Therapeutics' Times Interest Earned averaged around -$9955.0, with its median value being -$8444.0 (2020).
  • As far as peak fluctuations go, Keros Therapeutics' Times Interest Earned plummeted by 72338.74% in 2020, and later skyrocketed by 6338.88% in 2021.
  • Over the past 4 years, Keros Therapeutics' Times Interest Earned (Quarter) stood at -$775.33 in 2019, then crashed by 1614.23% to -$13291.0 in 2020, then skyrocketed by 63.39% to -$4866.0 in 2021, then tumbled by 395.81% to -$24126.0 in 2022.
  • Its Times Interest Earned was -$24126.0 in Q1 2022, compared to -$4866.0 in Q4 2021 and -$20197.0 in Q3 2021.